BioCryst Pharma (BCRX) Misses Q4 EPS by 5c, Miss on Revenues; Offers FY18 Financial Guidance & Clinical Outlook
Go back to BioCryst Pharma (BCRX) Misses Q4 EPS by 5c, Miss on Revenues; Offers FY18 Financial Guidance & Clinical Outlook| BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) | Delayed: 9.20 +0.21 (2.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.99 | 52 Week High | $10.98 | |||
| Open | $9.04 | 52 Week Low | $1.63 | |||
| Day High | $9.25 | P/E | N/A | |||
| Day Low | $8.91 | EPS | $-0.68 | |||
| Volume | 2,464,936 | |||||
